Fong I W
St Michael's Hospital, Department of Medicine, University of Toronto, Ontario, Canada.
Pharmacoeconomics. 1996 Jun;9(6):497-505. doi: 10.2165/00019053-199609060-00004.
Vulvovaginal candidiasis (VVC) is a frequent cause of morbidity in women of reproductive age. Most women will experience 1 or 2 episodes in their lifetime, but a smaller population develop chronic recurrent disease. There are few data on cost or pharmacoeconomic considerations in the management of this condition. The disease does not usually result in long term disability, loss of employment or death, but could affect a woman's work performance through irritability, frustration and unhappiness. This review attempts to estimate the least costly programme or regimen (as the efficacy of different regimens is similar) that would be applicable to patients, third-party payers and society. Nonprescription or over-the-counter (OTC) antifungal preparations could have an impact on overall cost in the management of VVC. In the management of infrequent acute VVC, an OTC preparation would be least costly to the healthcare system (provided that the diagnosis was correct). The strategies used to control symptoms in patients with chronic recurrent VVC should be based on the frequency of recurrent episodes. For patients with less than 12 episodes a year, empirical self-treatment at the onset of symptoms with an OTC agent (e.g. intravaginal clotrimazole 500mg) is less costly and preferable to patients than monthly prophylaxis. Patients with a greater frequency of recurrences may benefit from monthly, daily or twice weekly prophylaxis. At present, for very frequent recurrences, intravaginal clotrimazole 200mg twice weekly appears to be as effective as daily oral ketoconazole, and may be safer and less costly. However, because of the lack of prospective controlled studies, most of these recommendations are based on hypothetical reasonings. Furthermore, the disadvantages of OTC antifungals include the potential for overuse and inappropriate use, possibly resulting in the delayed diagnosis and treatment of other conditions. On balance, OTC preparations may provide patients with faster and more economical care, and improve healthcare delivery.
外阴阴道念珠菌病(VVC)是育龄女性发病的常见原因。大多数女性一生中会经历1至2次发作,但有一小部分人会发展为慢性复发性疾病。关于这种疾病管理中的成本或药物经济学考量的数据很少。该疾病通常不会导致长期残疾、失业或死亡,但可能通过易怒、沮丧和不开心影响女性的工作表现。本综述试图估算适用于患者、第三方支付者和社会的成本最低的方案或治疗方案(因为不同治疗方案的疗效相似)。非处方或非处方药(OTC)抗真菌制剂可能会对VVC管理的总体成本产生影响。在治疗偶发性急性VVC时,OTC制剂对医疗系统来说成本最低(前提是诊断正确)。控制慢性复发性VVC患者症状的策略应基于复发发作的频率。对于每年发作少于12次的患者,在症状发作时使用OTC药物(如阴道用克霉唑500mg)进行经验性自我治疗,成本更低,对患者来说比每月预防性用药更可取。复发频率更高的患者可能从每月、每日或每周两次的预防性用药中获益。目前,对于非常频繁的复发,阴道用克霉唑200mg每周两次似乎与每日口服酮康唑一样有效,而且可能更安全、成本更低。然而,由于缺乏前瞻性对照研究,这些建议大多基于假设推理。此外,OTC抗真菌药物的缺点包括可能过度使用和不当使用,这可能导致其他疾病的诊断和治疗延迟。总体而言,OTC制剂可能为患者提供更快、更经济的护理,并改善医疗服务。